POOR ERYTHROID ENGRAFTMENT
Clinical trials for POOR ERYTHROID ENGRAFTMENT explained in plain language.
Never miss a new study
Get alerted when new POOR ERYTHROID ENGRAFTMENT trials appear
Sign up with your email to follow new studies for POOR ERYTHROID ENGRAFTMENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to boost red blood cells after transplant
Disease control Not yet recruitingThis study compares luspatercept to epoetin for patients with blood cancers who have poor red blood cell recovery after a stem cell transplant. About 90 adults will receive either drug every three weeks for 24 weeks. The goal is to see which treatment better reduces the need for …
Matched conditions: POOR ERYTHROID ENGRAFTMENT
Phase: PHASE2, PHASE3 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug aims to stop anemia after stem cell transplants
Disease control Not yet recruitingThis study tests whether the drug luspatercept can prevent severe anemia (low red blood cells) after a stem cell transplant in people with blood cancers and a bone marrow condition called myelofibrosis. About 196 adults will receive either luspatercept or standard supportive care…
Matched conditions: POOR ERYTHROID ENGRAFTMENT
Phase: PHASE2, PHASE3 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC